Phosphodiesterase Type 5 (pde5) Inhibitor Therapy Therapeutics
1. Stendra patent expiration
Treatment: Treatment of erectile dysfunction
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6656935 | VIVUS LLC | Aromatic nitrogen-containing 6-membered cyclic compounds |
Apr, 2025
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7501409 | VIVUS LLC | Preparations for oral administration |
May, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 27, 2017 |
| New Dosing Schedule(D-140) | Sep 17, 2017 |
| M(M-282) | Oct 18, 2025 |
Drugs and Companies using AVANAFIL ingredient
NCE-1 date: 27 April, 2016
Market Authorisation Date: 27 April, 2012
Dosage: TABLET
How can I launch a generic of STENDRA before it's drug patent expiration?
More Information on Dosage
STENDRA family patents
